Author: Hexagon Bio, Inc.

Hexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload Mechanisms

October 23, 2026
Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC

June 22, 2026

Hexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload Mechanisms